FI915149A0 - Foerfarande och material foer expression av humant plasminogen i ett eukaryotiskt cellsystem som saknar en laegesspecifik plasminogenaktivator. - Google Patents

Foerfarande och material foer expression av humant plasminogen i ett eukaryotiskt cellsystem som saknar en laegesspecifik plasminogenaktivator.

Info

Publication number
FI915149A0
FI915149A0 FI915149A FI915149A FI915149A0 FI 915149 A0 FI915149 A0 FI 915149A0 FI 915149 A FI915149 A FI 915149A FI 915149 A FI915149 A FI 915149A FI 915149 A0 FI915149 A0 FI 915149A0
Authority
FI
Finland
Prior art keywords
plasminogen
expression
saknar
laegesspecifik
eukaryotiskt
Prior art date
Application number
FI915149A
Other languages
English (en)
Finnish (fi)
Inventor
Francis J Castellino
Joann L Whitefleet-Smith
Elliot D Rosen
James H Mclinden
Original Assignee
Univ Notre Dame Du Lac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Notre Dame Du Lac filed Critical Univ Notre Dame Du Lac
Publication of FI915149A0 publication Critical patent/FI915149A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153Streptokinase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6435Plasmin (3.4.21.7), i.e. fibrinolysin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21007Plasmin (3.4.21.7), i.e. fibrinolysin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI915149A 1989-05-01 1991-10-31 Foerfarande och material foer expression av humant plasminogen i ett eukaryotiskt cellsystem som saknar en laegesspecifik plasminogenaktivator. FI915149A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34580189A 1989-05-01 1989-05-01
PCT/US1990/002296 WO1990013640A1 (en) 1989-05-01 1990-04-26 Methods and materials for expression of human plasminogen in a eukaryotic cell system

Publications (1)

Publication Number Publication Date
FI915149A0 true FI915149A0 (fi) 1991-10-31

Family

ID=23356538

Family Applications (1)

Application Number Title Priority Date Filing Date
FI915149A FI915149A0 (fi) 1989-05-01 1991-10-31 Foerfarande och material foer expression av humant plasminogen i ett eukaryotiskt cellsystem som saknar en laegesspecifik plasminogenaktivator.

Country Status (6)

Country Link
EP (1) EP0467987A4 (ja)
JP (1) JPH05500748A (ja)
AU (1) AU647391B2 (ja)
FI (1) FI915149A0 (ja)
PT (1) PT93933A (ja)
WO (1) WO1990013640A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US6743623B2 (en) 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US6099831A (en) * 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
CN100491394C (zh) 2000-11-28 2009-05-27 大卫·M·崴斯曼 抗血管增生的多肽
JP4047170B2 (ja) 2000-12-21 2008-02-13 トロム−イクス・ナムローゼ・フエンノートシャップ 酵母発現ベクターおよび酵母細胞における発現による組換えタンパク質の製造方法
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
WO2004054517A2 (en) 2002-12-13 2004-07-01 Mediomics, Llc Compositions and methods for inhibiting tumor growth and metastasis
EP2435562A1 (en) * 2009-05-26 2012-04-04 Biolex Therapeutics, Inc. Compositions and methods for production of aglycosylated plasminogen
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
CN103384722B (zh) 2011-01-05 2016-11-16 斯路姆基因公司 纤溶酶原和纤溶酶变体
KR20140064841A (ko) 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. 플라스미노겐 변이체 및 플라스민 변이체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943245A (en) * 1974-02-14 1976-03-09 Armour Pharmaceutical Company Purification of plasminogen
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector

Also Published As

Publication number Publication date
EP0467987A1 (en) 1992-01-29
JPH05500748A (ja) 1993-02-18
WO1990013640A1 (en) 1990-11-15
AU647391B2 (en) 1994-03-24
AU5659690A (en) 1990-11-29
EP0467987A4 (en) 1992-07-08
PT93933A (pt) 1991-01-08

Similar Documents

Publication Publication Date Title
FI915149A0 (fi) Foerfarande och material foer expression av humant plasminogen i ett eukaryotiskt cellsystem som saknar en laegesspecifik plasminogenaktivator.
ATE349540T1 (de) Expression der bazillus thuringiensis cry- proteine in pflanzen-plastiden
DK91389A (da) Kallikreiner, deres fremstilling og laegemidler indeholdende polypeptiderne
FI905919A (fi) Foerfarande och material foer expression av en human plasminogenvariant.
GB8623615D0 (en) Enhancing t-pa & scu-pa production
DK0669394T3 (da) Bifunktionelle urokinasevarianter med forbedrede fibrinolytiske egenskaber og thrombinhæmmende virkninger
IL86058A (en) Specifically glycosylates urokinase-type plasminogen activators, their preparation, hybrid vectors and transformed yeast containing them and pharmaceutical compositions containing such activators
ATE139571T1 (de) Rekombinante dna-expressionsvektoren und dna- zusammensetzungen, die isopenizillin n-epimerase- aktivität kodieren
KR890701733A (ko) 신규 인체 조직형 플리스미노겐 활성제 변이체

Legal Events

Date Code Title Description
FD Application lapsed